Abstract
Stenotrophomonas maltophilia is an emerging multidrug-resistant (MDR) opportunistic pathogen for which new antibiotic options are urgently needed. We report our clinical experience treating a 19-year-old renal transplant recipient who developed prolonged bacteremia due to metallo-β-lactamase-producing S. maltophilia refractory to conventional treatment. The infection recurred despite a prolonged course of colistimethate sodium (colistin) but resolved with the use of a novel drug combination with clinical efficacy against the patient's S. maltophilia isolate.
Original language | English (US) |
---|---|
Pages (from-to) | 5130-5134 |
Number of pages | 5 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 60 |
Issue number | 9 |
DOIs | |
State | Published - Sep 1 2016 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases